Developing a simulator to improve immune cell access to cancer cells
Integrated Immune Engineering for Poor Prognosis Cancers
This study is working on a special computer model that helps us understand how cancer and immune cells interact, which could lead to better treatments for tough cancers like pancreatic and brain cancer, and it’s designed for researchers and doctors looking to improve immunotherapy options.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10896022 on NIH RePORTER |
What this research studies
This research focuses on creating a multiscale tumor simulator that predicts how immune and cancer cells interact and migrate. By using advanced live cell microscopy, the team will quantitatively measure these interactions to enhance the effectiveness of immunotherapies, particularly for challenging cancers like pancreatic ductal adenocarcinoma and glioblastoma. The simulator will integrate various engineering approaches to refine immunotherapy strategies, allowing for experimental testing of predictions made by the model. This collaborative effort involves biomedical engineers, immunologists, and genetic engineers working together to improve cancer treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma or glioblastoma who are seeking innovative treatment options.
Not a fit: Patients with cancers that are not targeted by this research or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapies for patients with poor prognosis cancers.
How similar studies have performed: Other research has shown promise in using computational models to enhance immunotherapy, indicating that this approach could be effective.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Odde, David J. — University of Minnesota
- Study coordinator: Odde, David J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.